Pfizer Inc. (NYSE:PFE) is among the undervalued wide moat stocks to buy now. Olema Pharmaceuticals has announced its collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in the treatment of metastatic breast cancer. Under the clinical trial partnership, both companies will examine the palazestrant-atirmociclib combination in approximately 35 patients, anticipated to begin in H2 2025. With Olema leading the study, Pfizer Inc. (NYSE:PFE) will serve as the supplier of atirmociclib for use in the Ph ...